COVID19S-REAAD Anti-SARS-CoV-2 Total Antibodies ELISA Assay Kit
The COVID19S-REAAD Anti-SARS-CoV-2 Total Antibodies ELISA is For Research Use Only
Size: 1×96 wells
Incubation Time: 45 minutes
Sample Type: Serum, plasma
Sample Size: 100 µl
Alternative Names: COVID-19, Coronavirus, SARS-CoV-2
Controls Included
Assay Background
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in December 2019, and has since spread globally, resulting in the ongoing pandemic. Majority of the cases result in mild symptoms, however some progress to pneumonia and multi-organ failure. The overall mortality rate for this disease was up to 4.6% (ranging from 0.2% to 15% according to age group and other health problems). SARS-CoV-2 is predominantly transmitted by droplet infection via coughing or sneezing and through close contact with infected persons. The incubation time of SARS-CoV-2 is three to seven, maximally 14 days. It has been reported that PCR-confirmed SARS-CoV-2 positive patients may seroconvert and develop antibodies against SARS-CoV-2 antigens anywhere from 6-21 days after the onset of clinical symptoms. The specific and reliable detection of human IgG antibodies to SARS-CoV-2 remains a key method to monitor infections, to effect contact tracing, for serosurveillance, and to monitor antibody titers after vaccination. COVID19S-REAAD™ detects total antibodies (neutralizing antibodies) against SARS-CoV-2 spike 1 receptor-binding domain (S1-RBD) glycoproteins.
Related Products
Product manufactured by Restalyst.
